Chronic obstructive pulmonary disease exacerbation resident survival guide: Difference between revisions
Gerald Chi (talk | contribs) m (→Management) |
|||
Line 66: | Line 66: | ||
<sup>†</sup><small>''Pa<sub>O<sub>2</sub></sub> <60 mm Hg with or without Pa<sub>CO<sub>2</sub></sub> >50 mm Hg in ambient air''</small> | <sup>†</sup><small>''Pa<sub>O<sub>2</sub></sub> <60 mm Hg with or without Pa<sub>CO<sub>2</sub></sub> >50 mm Hg in ambient air''</small> | ||
{{Family tree/start}} | |||
{{Family tree | | | | A01 | | | |A01= '''COPD Exacerbation'''<br>↑[[cough]], ↑[[dyspnea]], ↑[[sputum]], <br> ↑[[wheezing]], [[fever]] or chest tightness}} | |||
{{Family tree | | | | |!| | | | | }} | |||
{{Family tree | | | | B01 | | | |B01=Admission}} | |||
{{Family tree | | | | |!| | | | |}} | |||
{{Family tree | | | | C01 |~| C02 | |C01='''Assessment''' :<br>1-O2 sat+ ABG <br>2-[[CXR]] <br>3-[[EKG]] <br>4-[[CBC]] | |||
<br> | |||
'''Management:''' <br>1-Inhaled bronchodilators <br>2-Systemic corticosteroids <br>3-Empirical antibiotics <br>4-O2 (target Sat >90%)|C02='''Corticosteroids(Solumedrol)'''<br>Methylprednisolone 125 mg×1 dose <br> followed with 60-80 mg Q8-12based on severity <br> IV Solumedrol to PO Prednisone taper 4--60 mg Q 8-12<br> 2-5 days taper depending on severity<br> '''Antibiotics'''<br>'''Group A'''*<br>Doxycycline Cap '''Vibramycin''' PO 100 mg Q12H<br>(if unable to tolerate choose Cefpodoxime Tab '''Vantin''' PO 200 mg Q12H)<br>'''Group B'''*<br>Ceftriaxone Inj '''Rocephin''' 1GM D5W50 ml Q24H 200 ml/Hr<br>(If Beta-Lactam allergy choose Levofloxacin Tab '''Levaquin''' PO 500 mg daily )<br> '''Group C'''*<br>Ciprofloxacin Tab '''Cipro'''PO 250 Daily<br>or Ciprofloxacin Inj Cipro 400 mg premixed at 400 mg /200 ml Q12H 200 ml/Hr. | |||
}} | |||
{{Family tree | | | | |!| | | | |}} | |||
{{Family tree | | | | D01 | | | |D01=Respiratory acidosis? OR <br> PH≤35? OR<br> PaCo2≥45? OR<br> Severe signs of dyspnea? OR <br>Accessory muscles use,<br>paradoxical motion of abdomen,<br> retraction of intercostal space}} | |||
{{Family tree | | |,|-|^|-|.| | }} | |||
{{Family tree | E01 | | | E02 |E01=No | E02= Yes}} | |||
{{Family tree | |!| | | | |!| |}} | |||
{{Family tree | F01 | | | F02|F01=Continue the same management |F02='''ICU Admission''' }} | |||
{{family tree | | | | | | |!| | | | | | |}} | |||
{{family tree | | | | | | |z| | | | | | |z=Non-invasive ventilation}} | |||
{{Family tree | | | | | | |!| |}} | |||
{{Family tree | | | | | | G01 |G01= Unable to tolerate NIV?<br> Severe hemodynamic instability?<br>Resp/cardiac arrest ? }} | |||
{{Family tree | | | | | | |!| | |}} | |||
{{Family tree | | | | | | H01 | |H01=Invasive mechanical ventilation}} | |||
{{Family tree/end}} | |||
==Do's== | ==Do's== |
Revision as of 22:32, 12 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Definition
- An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.[1][2][3]
- The diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.[4]
Causes
Life Threatening Causes
Include conditions which may result death or permanent disability within 24 hours if left untreated, and some of them may mimic and/or aggravate exacerbations:
Common Causes
- Respiratory tract infections (~½)
- Unknown (~⅓)
- Air pollutants
Differential Diagnosis
Management
COPD Exacerbation ❑ Cough ↑ ❑ Dyspnea ↑ ❑ Sputum ↑ | |||||||||||||||||||||
Oxygen Supplement Indications for ICU Admission Indications for Hospitalization Assessment of Severity of Exacerbation | |||||||||||||||||||||
123 | |||||||||||||||||||||
†PaO2 <60 mm Hg with or without PaCO2 >50 mm Hg in ambient air
COPD Exacerbation ↑cough, ↑dyspnea, ↑sputum, ↑wheezing, fever or chest tightness | |||||||||||||||||||||||||||||
Admission | |||||||||||||||||||||||||||||
Assessment : 1-O2 sat+ ABG 2-CXR 3-EKG 4-CBC
1-Inhaled bronchodilators 2-Systemic corticosteroids 3-Empirical antibiotics 4-O2 (target Sat >90%) | Corticosteroids(Solumedrol) Methylprednisolone 125 mg×1 dose followed with 60-80 mg Q8-12based on severity IV Solumedrol to PO Prednisone taper 4--60 mg Q 8-12 2-5 days taper depending on severity Antibiotics Group A* Doxycycline Cap Vibramycin PO 100 mg Q12H (if unable to tolerate choose Cefpodoxime Tab Vantin PO 200 mg Q12H) Group B* Ceftriaxone Inj Rocephin 1GM D5W50 ml Q24H 200 ml/Hr (If Beta-Lactam allergy choose Levofloxacin Tab Levaquin PO 500 mg daily ) Group C* Ciprofloxacin Tab CiproPO 250 Daily or Ciprofloxacin Inj Cipro 400 mg premixed at 400 mg /200 ml Q12H 200 ml/Hr. | ||||||||||||||||||||||||||||
Respiratory acidosis? OR PH≤35? OR PaCo2≥45? OR Severe signs of dyspnea? OR Accessory muscles use, paradoxical motion of abdomen, retraction of intercostal space | |||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||
Continue the same management | ICU Admission | ||||||||||||||||||||||||||||
Non-invasive ventilation | |||||||||||||||||||||||||||||
Unable to tolerate NIV? Severe hemodynamic instability? Resp/cardiac arrest ? | |||||||||||||||||||||||||||||
Invasive mechanical ventilation | |||||||||||||||||||||||||||||
Do's
- Monitor fluid balance,nutrition and patient condition closely.
- Consider subcutaneous heparin or low molecular weight heparin.
- Treat associated conditions if exist(e.g., heart failure,arrhythmias).
Don'ts
- Spirometry is not recommended during an exacerbation because it can be difficult to perform and measurements are not accurate enough.
References
- ↑ Burge, S.; Wedzicha, JA. (2003). "COPD exacerbations: definitions and classifications". Eur Respir J Suppl. 41: 46s–53s. PMID 12795331. Unknown parameter
|month=
ignored (help) - ↑ Celli, BR.; Barnes, PJ. (2007). "Exacerbations of chronic obstructive pulmonary disease". Eur Respir J. 29 (6): 1224–38. doi:10.1183/09031936.00109906. PMID 17540785. Unknown parameter
|month=
ignored (help) - ↑ Rodriguez-Roisin, R. (2000). "Toward a consensus definition for COPD exacerbations". Chest. 117 (5 Suppl 2): 398S–401S. PMID 10843984. Unknown parameter
|month=
ignored (help) - ↑ Vestbo, J.; Hurd, SS.; Agustí, AG.; Jones, PW.; Vogelmeier, C.; Anzueto, A.; Barnes, PJ.; Fabbri, LM.; Martinez, FJ. (2013). "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary". Am J Respir Crit Care Med. 187 (4): 347–65. doi:10.1164/rccm.201204-0596PP. PMID 22878278. Unknown parameter
|month=
ignored (help) - ↑ Austin, MA.; Wills, KE.; Blizzard, L.; Walters, EH.; Wood-Baker, R. (2010). "Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial". BMJ. 341: c5462. PMID 20959284.